4.3 Article

An antibody to IP-10 is a potent antagonist of cell migration in vitro and in vivo and does not affect disease in several animal models of inflammation

Related references

Note: Only part of the references are listed.
Article Biochemical Research Methods

Development of a novel chemokine-mediated in vivo T cell recruitment assay

Gabriele S. V. Campanella et al.

JOURNAL OF IMMUNOLOGICAL METHODS (2008)

Article Immunology

Oligomerization of CXCL10 is necessary for endothelial cell presentation and in vivo activity

Gabriele S. V. Campanella et al.

JOURNAL OF IMMUNOLOGY (2006)

Article Pharmacology & Pharmacy

Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist

CE Heise et al.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)

Article Immunology

Inhibition of IFN-γ-inducible protein-10 abrogates colitis in IL-10-/- mice

UP Singh et al.

JOURNAL OF IMMUNOLOGY (2003)

Article Multidisciplinary Sciences

Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines

AEI Proudfoot et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)

Article Biochemistry & Molecular Biology

The CXCR3 binding chemokine IP-10/CXCL10: Structure and receptor interactions

V Booth et al.

BIOCHEMISTRY (2002)

Article Immunology

Donor-derived IP-10 initiates development of acute allograft rejection

WW Hancock et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2001)

Article Biochemistry & Molecular Biology

The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3

P Loetscher et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2001)

Article Immunology

CXCR3 and CCR5 ligands in rheumatoid arthritis synovium

DD Patel et al.

CLINICAL IMMUNOLOGY (2001)

Article Immunology

Requirement of the chemokine receptor CXCR3 for acute allograft rejection

WW Hancock et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2000)